Ventyx Biosciences’ (VTYX) Outperform Rating Reaffirmed at Oppenheimer

Ventyx Biosciences (NASDAQ:VTYX)‘s stock had its “outperform” rating reaffirmed by research analysts at Oppenheimer in a research report issued on Friday,Benzinga reports. They currently have a $9.00 price objective on the stock, down from their previous price objective of $10.00. Oppenheimer’s price objective would suggest a potential upside of 305.41% from the company’s previous close.

Several other analysts also recently issued reports on the stock. Canaccord Genuity Group decreased their price objective on shares of Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating for the company in a report on Monday, August 12th. Wells Fargo & Company cut their target price on shares of Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating for the company in a research note on Monday, August 12th. Finally, HC Wainwright reiterated a “neutral” rating and set a $6.00 target price on shares of Ventyx Biosciences in a research note on Tuesday, October 15th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Ventyx Biosciences presently has a consensus rating of “Moderate Buy” and an average target price of $9.00.

Ventyx Biosciences Stock Down 0.9 %

VTYX stock traded down $0.02 during trading hours on Friday, hitting $2.22. The company’s stock had a trading volume of 394,654 shares, compared to its average volume of 2,053,604. The stock has a 50 day moving average price of $2.24 and a two-hundred day moving average price of $2.85. The company has a market capitalization of $156.89 million, a PE ratio of -0.80 and a beta of 0.37. Ventyx Biosciences has a 12 month low of $1.79 and a 12 month high of $11.48.

Ventyx Biosciences (NASDAQ:VTYX) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.12. Sell-side analysts expect that Ventyx Biosciences will post -2.14 earnings per share for the current year.

Hedge Funds Weigh In On Ventyx Biosciences

A number of hedge funds have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. raised its stake in shares of Ventyx Biosciences by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company’s stock valued at $30,000 after buying an additional 5,310 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Ventyx Biosciences by 41.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company’s stock worth $56,000 after purchasing an additional 7,096 shares during the last quarter. Norden Group LLC bought a new stake in shares of Ventyx Biosciences in the 1st quarter worth about $59,000. Palumbo Wealth Management LLC bought a new stake in shares of Ventyx Biosciences in the 3rd quarter worth about $26,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Ventyx Biosciences in the 1st quarter worth about $72,000. Institutional investors and hedge funds own 97.88% of the company’s stock.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.